Preparing Belgium for the future of precision oncology
Cancer care is evolving rapidly. New precision medicines and targeted therapies offer patients more personalised treatment options, improving outcomes while using healthcare resources more effectively. However, these innovations also place increasing pressure on healthcare budgets and reimbursement systems.
This report explores how Belgium can prepare for the next generation of precision oncology by improving access to innovative treatments while ensuring long-term sustainability of the healthcare system.
Anticipating the next wave of cancer innovation.
The report analyses the growing pipeline of precision medicines expected to reach the market over the coming years. Alongside these new therapies, advanced diagnostic technologies are becoming increasingly important to identify which patients are most likely to benefit from personalised treatment.
By combining therapeutic innovation with modern diagnostics, healthcare providers can deliver more targeted and effective care while avoiding unnecessary treatments.
Improving patient access to innovative treatments.
One of the report's key findings is that Belgium's reimbursement and approval processes need to evolve to keep pace with medical innovation.
The publication recommends:
Faster access to innovative cancer therapies.
Better alignment between drug approval and diagnostic reimbursement.
More efficient evaluation processes for personalised treatments.
Improved collaboration between healthcare decision-makers.
These recommendations aim to reduce delays so patients can benefit from new therapies sooner.
Smarter healthcare budgeting.
Precision oncology is expected to account for a growing share of healthcare spending in the coming years. Rather than reacting after new treatments become available, the report proposes a forward-looking budgeting approach.
By using horizon scanning and long-term forecasting, healthcare systems can better anticipate future investments while maintaining financial sustainability.
Better decisions through precision diagnostics.
The publication also highlights the essential role of diagnostic testing in personalised medicine.
Accurate diagnostics help ensure that patients receive the treatments most likely to benefit them, while reducing ineffective therapies, unnecessary healthcare costs, and avoidable side effects. Better diagnostics ultimately lead to better clinical outcomes and more efficient use of healthcare resources.
Building a more sustainable healthcare system.
Beyond improving access to innovation, the report demonstrates how strategic planning can help healthcare systems remain sustainable as medical technology continues to evolve.
By combining early forecasting, coordinated decision-making and evidence-based budgeting, Belgium can continue to provide patients with access to cutting-edge cancer treatments while ensuring responsible use of public healthcare resources.
Read the full publication.
Interested in how Belgium can prepare for the future of precision oncology?